Gain Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
GANX$1.09+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Net loss | | $(20,161,099) | | $(20,411,191) | ||
| Components of other comprehensive (loss) income | | | | | | |
| Unrealized gain on available-for-sale marketable securities | | | — | | | 4,974 |
| Changes in defined benefit pension plan obligation, net of tax | | | 177,214 | | | (132,524) |
| Foreign currency translation | | 847,204 | | (367,240) | ||
| Other comprehensive income (loss), net of tax | | | 1,024,418 | | | (494,790) |
| Comprehensive loss | | $(19,136,681) | | $(20,905,981) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.